The fen-phen epidemic of pulmonary hypertension

Fen-phen was a combination of two weight loss drugs, fenfluramine and phentermine, widely prescribed to combat obesity. However, it was soon discovered that this combination led to serious health complications, particularly pulmonary hypertension.

The epidemic prompted swift action from regulatory authorities. In 1997, the FDA recommended the withdrawal of fenfluramine and dexfenfluramine (a related drug) from the market. This decision came after reports of valvular heart disease and pulmonary hypertension in fen-phen users. Lawsuits against pharmaceutical companies followed, leading to substantial legal settlements.

The fen-phen epidemic serves as a stark reminder of the importance of rigorous drug testing and monitoring. It also underscores the need for transparency in the pharmaceutical industry. While weight loss drugs can offer benefits, their potential risks must be thoroughly understood to protect the health of patients.